Proliferative response of human prostate cancer cell to hormone inhibited by androgen receptor antisense RNA

Chinese Medical Journal

Volumn 117, Issue 5, 2004, Pages 684-688

  Jiang, Jun ^a   Wang, Luo Fu ^a   Fang, Yu Hua ^a   Jin, Feng Shuo ^a   Jin, Wen Sheng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Androgen receptor; Antisense RNA; Prostatic neoplasms

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; COMPLEMENTARY RNA; ESTRADIOL; METRIBOLONE; PROGESTERONE; RETROVIRUS VECTOR;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; DRUG RECEPTOR BINDING; GENETIC TRANSFECTION; HORMONE INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; VIRAL GENE DELIVERY SYSTEM;

CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; HUMANS; MALE; METRIBOLONE; PROGESTERONE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, ANTISENSE;

EID: 2942597961     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002; 60 (Suppl 1): 132-138.
2. Culig Z, Klocker H, Bartsch G, et al. Androgen receptors in prostate cancer. Endocr Relat Cancer 2002;9:155-170.
3. Culig Z, Klocker H, Bartsch G, et al. Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy. Am J Pharmacogenomics 2001; 1: 241-249.
4. Koivisto P, Kolmer M, Visakorpi T, et al. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998;152:1-9.
5. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173:534-540.
6. Rini BI, Small EJ. Prostate cancer update. Curr Opin Oncol 2002; 14:286-291.
7. Jenster G. The role of androgen receptor in the development and progression of prostate cancer. Semin Oncol 1999;26: 407-421.
8. Navarro D, Luzardo OP, Fernandez L, et al. Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 2002;81:191-201.
9. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nature Rev Cancer 2001;1:34-45.
10. Edwards J, Krishna NS, Grigor KM, et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89:552-556.
11. Tyrrell CJ, Blake GM, Iversen P, et al. The non-steroidal antiandrogen, bicalutamide ("Casodex"), may preserve bone mineral density as compared with castration: results of a preliminary study. World J Urol 2003;21:3742.
12. Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003;15:2673-2678.
13. Taplin ME, Rubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-1398.
14. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced-stage prostate carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993;7:1541-1550.
15. Susuki H, Akakura K, Komiya A, et al. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996; 29:153-158.
16. Gleave M, Miyake H, Zangemeister WU, et al. Antisense therapy: current status in prostate cancer and other malignancies. Cancer Metastasis Rev 2002;21:79-92.
17. Wang L, Jiang J, Fang Y, et al. Construction and identification of antisense AR RNA retroviral vector. Acta Academiae Medicinae Militaris Tertiae (Chin) 2001;23:641-643.
18. Jiang J, Wang LF, Fang YH, et al. Inhibited expression of andorgen receptor in prostate cancer cells by antisense androgen receptor RNA. Acta Academiae Medicinae Militaris Tertiae (Chin) 2003;25:501-504.
19. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 1995;83:851-857.
20. Eder IE, Culig Z, Ramoner R, et al. Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 2000;7:997-1007.
21. Grigorgv DN, Long BJ, Njar VC, et al. Pregnenolone stimulates LNCaP prostate cancer cell growth via mutated androgen receptor. J Steroid Biochen Biol 2000;75:1-10.
22. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-319.
23. Jenster G. Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines. J Pathol 2000;191:227-228.
24. Miyamoto H, Yeh S, Wilding G, et al. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 1998;95:7379-7384.
25. Harris SE, Rong Z, Harris MA, et al. Androgen receptor in human prostate carcioma LNCaP/ADEP cells contains a mutation which alters the specificity of the steroid-dependent transcriptional activatin region. Endocrinology 1990; 126 (Suppl):93.
26. Paul R, Breul J. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Dru-Saf 2000;23:381-390.